Informing Canada's cancer drug funding decisions with scientific evidence and patient perspectives: the Pan-Canadian Oncology Drug Review.
作者信息
Hoch J S, Sabharwal M
机构信息
Pharmacoeconomics Research Unit, Cancer Care Ontario, and Canadian Centre for Applied Research in Cancer Control, Toronto, ON.
出版信息
Curr Oncol. 2013 Apr;20(2):121-4. doi: 10.3747/co.20.1315.
Abstract
摘要
相似文献
1
Informing Canada's cancer drug funding decisions with scientific evidence and patient perspectives: the Pan-Canadian Oncology Drug Review.利用科学证据和患者观点为加拿大癌症药物资助决策提供信息：泛加拿大肿瘤药物审查
Curr Oncol. 2013 Apr;20(2):121-4. doi: 10.3747/co.20.1315.
2
Meaningful patient representation informing Canada's cancer drug funding decisions: views of patient representatives on the Pan-Canadian Oncology Drug Review.有意义的患者代表参与，为加拿大癌症药物资助决策提供信息：泛加拿大肿瘤药物评审中患者代表的观点。
Curr Oncol. 2014 Oct;21(5):263-6. doi: 10.3747/co.21.2128.
3
Impact of the pan-Canadian Oncology Drug Review on provincial concordance with respect to cancer drug funding decisions and time to funding.泛加拿大肿瘤药物审查对各省在癌症药物资金决策和资金到位时间方面的一致性的影响。
Curr Oncol. 2017 Oct;24(5):295-301. doi: 10.3747/co.24.3648. Epub 2017 Oct 25.
4
Using a rapid environmental scan methodology to map country-level global health research expertise in Canada.运用快速环境扫描方法绘制加拿大国家级全球卫生研究专业知识图谱。
Health Res Policy Syst. 2020 Apr 9;18(1):37. doi: 10.1186/s12961-020-0543-x.
5
[Reluctant partner: Canada's relationship with the Pan American Health Organization (PAHO)].[不情愿的伙伴：加拿大与泛美卫生组织（PAHO）的关系]
Hist Cienc Saude Manguinhos. 2006 Jul-Sep;13(3):717-32. doi: 10.1590/s0104-59702006000300009.
6
Challenges in striving to simultaneously achieve multiple resource allocation goals: the pan-Canadian Oncology Drug Review (pCODR) example.在努力同时实现多个资源分配目标时面临的挑战：以泛加拿大肿瘤药物审查（pCODR）为例。
J Mark Access Health Policy. 2016 Jul 21;4. doi: 10.3402/jmahp.v4.31463. eCollection 2016.
7
Strategizing health technology assessment for containment of cancer drug costs in a universal health care system: Case of the pan-Canadian Oncology Drug Review.制定卫生技术评估策略以控制全民医疗保健系统中的癌症药物费用：以加拿大泛癌种药物评审为例。
Cancer. 2019 Sep 15;125(18):3100-3103. doi: 10.1002/cncr.32209. Epub 2019 Jun 2.
8
Activities of the pan-Canadian Pharmaceutical Alliance: An Observational Analysis.泛加拿大制药联盟的活动：一项观察性分析。
J Popul Ther Clin Pharmacol. 2018 Aug 7;25(2):e12-e22. doi: 10.22374/1710-6222.25.2.2.
9
New Cancer Drug Approvals From the Perspective of a Universal Healthcare System: Analyses of the Pan-Canadian Oncology Drug Review Recommendations.从全民医疗保健系统的角度看新癌症药物的审批：对全加肿瘤药物评审建议的分析。
J Natl Compr Canc Netw. 2018 Dec;16(12):1460-1466. doi: 10.6004/jnccn.2018.7084.
10
Canada's contribution to global research in cardiovascular diseases.加拿大在心血管疾病全球研究中的贡献。
Can J Cardiol. 2013 Jun;29(6):742-6. doi: 10.1016/j.cjca.2012.09.013. Epub 2012 Dec 6.
引用本文的文献
1
Considerations when applying equity weights within economic evaluation when making drug reimbursement decisions.在做出药品报销决策时，在经济评估中应用公平权重时的考量因素。
Health Econ Rev. 2024 Nov 13;14(1):90. doi: 10.1186/s13561-024-00556-w.
2
Analyzing a Cost-Effectiveness Dataset: A Speech and Language Example for Clinicians.分析成本效益数据集：临床医生的言语和语言示例。
Semin Speech Lang. 2022 Jun;43(3):244-254. doi: 10.1055/s-0042-1750347. Epub 2022 Jul 20.
3
Comparing Manufacturer Submitted and Pan-Canadian Oncology Drug Review Reanalysed Incremental Cost-Effectiveness Ratios for Novel Oncology Drugs.比较制造商提交的和泛加瘤药物审查重新分析的新型瘤药物增量成本效益比。
Curr Oncol. 2021 Jan 20;28(1):606-618. doi: 10.3390/curroncol28010060.
4
Financial relationships between patient and consumer representatives and the health industry: A systematic review.患者和消费者代表与卫生行业之间的财务关系：系统评价。
Health Expect. 2020 Apr;23(2):483-495. doi: 10.1111/hex.13013. Epub 2019 Dec 19.
5
Potential Life-Years Lost: The Impact of the Cancer Drug Regulatory and Funding Process in Canada.潜在生命年损失：加拿大癌症药物监管和筹资过程的影响。
Oncologist. 2020 Jan;25(1):e130-e137. doi: 10.1634/theoncologist.2019-0314. Epub 2019 Sep 10.
6
Advantages of the net benefit regression framework for trial-based economic evaluations of cancer treatments: an example from the Canadian Cancer Trials Group CO.17 trial.基于试验的癌症治疗经济学评价中净收益回归框架的优势：来自加拿大癌症临床试验组 CO.17 试验的实例。
BMC Cancer. 2019 Jun 7;19(1):552. doi: 10.1186/s12885-019-5779-x.
7
Addressing the affordability of cancer drugs: using deliberative public engagement to inform health policy.解决癌症药物可负担性问题：利用审议式公众参与为卫生政策提供信息。
Health Res Policy Syst. 2019 Feb 7;17(1):17. doi: 10.1186/s12961-019-0411-8.
8
Understanding the reasons for provincial discordance in cancer drug funding-a survey of policymakers.了解省级癌症药物资金不一致的原因——对政策制定者的一项调查
Curr Oncol. 2018 Aug;25(4):257-261. doi: 10.3747/co.25.3993. Epub 2018 Aug 14.
9
Methodological Issues in Economic Evaluations Submitted to the Pan-Canadian Oncology Drug Review (pCODR).提交给泛加拿大肿瘤药物评审（pCODR）的经济评估中的方法学问题。
Pharmacoecon Open. 2017 Dec;1(4):255-263. doi: 10.1007/s41669-017-0018-3.
10
Checkpoint Inhibitors, Palliative Care, or Hospice.免疫检查点抑制剂、姑息治疗或临终关怀。
Curr Oncol Rep. 2018 Jan 19;20(1):2. doi: 10.1007/s11912-018-0659-0.
本文引用的文献
1
American Society of Clinical Oncology guidance statement: the cost of cancer care.美国临床肿瘤学会指导声明：癌症护理的成本
J Clin Oncol. 2009 Aug 10;27(23):3868-74. doi: 10.1200/JCO.2009.23.1183. Epub 2009 Jul 6.
2
How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question.生命价值几何：西妥昔单抗、非小细胞肺癌与那4400亿美元的问题
J Natl Cancer Inst. 2009 Aug 5;101(15):1044-8. doi: 10.1093/jnci/djp177. Epub 2009 Jun 29.
3
Limits on Medicare's ability to control rising spending on cancer drugs.医疗保险在控制癌症药物支出不断上涨方面的能力限制。
N Engl J Med. 2009 Feb 5;360(6):626-33. doi: 10.1056/NEJMhpr0807774. Epub 2009 Jan 27.
Zotero 插件